Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07541573 · ClinicalTrials.gov registry record · Phase 1
GTB-5550 in Advanced Solid Tumors
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT07541573 is a Phase 1 study that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 175 participants.
The verdict
NCT07541573, a Phase 1 study, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers. To be considered for the study, a patient must be 18 years or older, have histologically or cytologically confirmed advanced/metastatic cancer that, based on literature reports, expresses B7-H3 at a high frequency, measurable disease by RECIST 1.1 (exception: mCRPC limited to bone metastasis are exempt from this requirement), meets the disease specific criteria for prior failed therapy, and refractory to, intolerant of, or ineligible for therapy options that are known to provide clinical benefit for their diagnosis.
Interventions
- DRUG GTB-5550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2032-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07541573
The ClinicalTrials.gov registry entry for NCT07541573 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GTB-5550 is the first listed.
NCT07541573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07541573 about?
NCT07541573 is a clinical study titled "GTB-5550 in Advanced Solid Tumors". This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers. To be considered for the study, a patient must be 18 years or older, have histologically or cytologic...
What is the current status of trial NCT07541573?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2026-04-08. Estimated completion is 2032-01.
What interventions are being tested in trial NCT07541573?
The interventions under investigation include: GTB-5550 (DRUG).
Who is sponsoring clinical trial NCT07541573?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.